Syprine
(Trientine)Phase 3Small molecule
Syprine is one of 43 small molecule programs targeting Wilson disease. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
42
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Hypertrophic Cardiomyopathy
#DrugCompanyPhaseTrials
1Aldactone
PfizerApproved
Zebeta
TevaApproved
Adenocard
AstellasApproved
Lexiscan
AstellasApproved
Bayer Aspirin
BayerApproved
Cardizem
BBausch Health Americas, Inc.
Approved
Camzyos
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Calan
VVal Adams
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertrophic Cardiomyopathy1 trial
Clinical Efficacy and Safety1 trial
Regulatory
FDA Approval Timeline[4]
Nov 8, 1985
SYPRINE
NDA NDA019194
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trientine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBausch Health Americas, Inc.